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Abstract
Cardiac progenitors are specified early in development and progressively differentiate and
mature into fully functional cardiomyocytes. This process is controlled by an extensively
studied transcriptional program. However, the regulatory events coordinating the progres-
sion of such program from development to maturation are largely unknown. Here, we show
that the genome organizer CTCF is essential for cardiogenesis and that it mediates genomic
interactions to coordinate cardiomyocyte differentiation and maturation in the developing
heart. Inactivation of Ctcf in cardiac progenitor cells and their derivatives in vivo during
development caused severe cardiac defects and death at embryonic day 12.5. Genome
wide expression analysis in Ctcf mutant hearts revealed that genes controlling mitochondrial
function and protein production, required for cardiomyocyte maturation, were upregulated.
However, mitochondria from mutant cardiomyocytes do not mature properly. In contrast,
multiple development regulatory genes near predicted heart enhancers, including genes in
the IrxA cluster, were downregulated in Ctcf mutants, suggesting that CTCF promotes cardi-
omyocyte differentiation by facilitating enhancer-promoter interactions. Accordingly, loss of
CTCF disrupts gene expression and chromatin interactions as shown by chromatin confor-
mation capture followed by deep sequencing. Furthermore, CRISPR-mediated deletion of
an intergenic CTCF site within the IrxA cluster alters gene expression in the developing
heart. Thus, CTCF mediates local regulatory interactions to coordinate transcriptional pro-
grams controlling transitions in morphology and function during heart development.
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Author summary
Properly regulated gene expression in time and space during development and differentia-
tion requires not only transcriptional inputs, but also specific structuring of the chroma-
tin. CTCF is a DNA binding factor that is believed to be critical for this process through
binding to tens of thousands of sites across the genome. Despite the knowledge gained in
recent years on the role of CTCF in genome organization, its functions in vivo are poorly
understood. To address this issue, we studied the effect of genetically deleting CTCF in
differentiating cardiomyocytes at early stages of mouse development. Surprisingly only a
fraction of genes change their expression when CTCF is removed. Importantly, misregu-
lated genes control opposing genetic programs in charge of development and patterning
on one hand, and cardiomyocyte maturation on the other. This imbalance leads to faulty
mitochondria and incorrect expression of cardiac patterning genes, and subsequent
embryonic lethality. Our results suggest that CTCF is not necessary for maintenance of
global genome structure, but coordinates dynamic genetic programs controlling pheno-
typic transitions in developing cells and tissues.
Introduction
The coordinated deployment of genetic programs during lineage commitment and differentia-
tion is a hallmark of developmental processes. Cell specification and maturation are coordi-
nated by controlled activation and repression of specific gene expression programs. In the
heart, the first functional organ in the embryo, activation of a core set of cardiogenic transcrip-
tion factors controls specification of cardiac progenitor cells [1]. Shortly after, high expression
of genes encoding sarcomeric components defines the contractile cardiomyocyte as early as
embryonic day (E) 8.5. Cardiomyocytes then mature by further sarcomere assembly [2], and
increased mitochondrial biogenesis [3, 4], and finally exit the cell cycle and become binucle-
ated at early postnatal stages [5].
Even though the genes and regulatory networks controlling morphogenesis and function in
the heart are well characterized [6], the events that coordinate the progression from differenti-
ation to maturation are not understood. Recent studies using both mouse and human pluripo-
tent cells have revealed that epigenomic landscapes and chromatin signatures dynamically
change during cardiomyocyte differentiation [7, 8], suggesting that chromatin structure might
control cardiogenesis. Chromatin conformational changes allow physical interaction of distal
regulatory elements in the genome. However, the chromatin interactions controlling expres-
sion of cardiac development and maturation are poorly understood.
The study of genome function during the last decade [9, 10] has provided an initial under-
standing of how functional elements scattered throughout the genome act coordinately to
control gene activity. The advent of tools to analyze interactions between distal regions of
chromatin [11] has allowed detailed mapping of the three-dimensional genome structure [12,
13] and its organization in distinct regulatory domains [14]. However, how these domains are
established, and their function in gene expression regulation are poorly understood. CTCF
(CCCTC-binding factor) is one of the best described architectural proteins with a role in chro-
matin structure organization. Through sequence specific binding to DNA, CTCF acts as a bar-
rier for heterochromatin spreading, establishes boundaries between adjacent topologically
associating domains (TADs), defines insulator elements that block enhancer activity on pro-
moters, and contributes to enhancer-promoter interactions [15, 16]. Loss of function studies
using knock-out and knock-down approaches have shown that CTCF is essential in early
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embryo development [17–19]. Conditional deletion of Ctcf in different developmental contexts
leads to defects in cell cycle progression [17], increased apoptosis [20, 21], and its deletion in
postmitotic neurons leads to decreases in the expression of clustered protocadherin genes [22].
Yet, we still do not fully understand how CTCF controls chromatin structure to coordinate
gene expression.
Here, we have studied how CTCF regulates gene expression in the context of the developing
mammalian heart. We deleted Ctcf in a population of cardiac progenitor cells, which results in
cardiac malformations and embryonic death. Analysis of global transcriptional changes pre-
ceding morphological defects caused by loss of CTCF showed downregulation of the cardiac
developmental program, and concomitant upregulation of programs involved in cardiomyo-
cyte maturation. This suggests that Ctcf deletion causes a premature arrest of cardiac develop-
ment and concomitantly promotes cardiomyocyte maturation. Thus, CTCF mediates local
chromatin interactions to coordinate transcriptional programs that control developmental
transitions in the heart.
Results
Cardiac specific deletion of Ctcf leads to embryonic lethality
To address the role of CTCF during development, we deleted Ctcf in cardiac progenitor cells
and their derivatives by using a floxed allele [17] and the Nkx2.5-Cre driver, which starts acting
as early as E7.5-E8.0 in cardiomyocyte precursors in the cardiac crescent [23]. E10.5 or E11.5
mutant (Ctcf fl/fl;Nkx2.5-Cre) embryos appeared normal and showed no gross morphological
alterations in the heart (Fig 1A–1D). At E12.5, mutant embryos presented pericardial edema
(Fig 1E) and the cardiac chambers did not expand properly (Fig 1F). Histological examination
showed no defects in E9.5 mutant hearts as compared to controls (Fig 1G and 1H). In E10.5
mutants, the four chambers and the atrioventricular canal formed properly, although the inter-
ventricular septum appeared slightly disorganized (Fig 1I and 1J). This defect was exacerbated
by E11.5, when thinning of the myocardial wall was also evident (Fig 1K and 1L). No mutant
embryos were recovered beyond E12.5 (S1 Table). Control Nkx2.5-Cre and compound Ctcf fl/+;
Nkx2.5-Cre heterozygotes showed normal morphology at these stages (S1 Fig).
To understand the effect of Ctcf deletion in the developing heart, we determined the time
point when CTCF protein was lost in cardiomyocytes. We performed co-immunostaining for
CTCF and the cardiomyocyte marker TNNT2 at different stages of heart development (S2
Fig). In E9.5 mutant hearts, 46% of cardiomyocytes still had detectable nuclear CTCF, albeit at
lower levels than in controls, in which all nuclei were double positive (S2A and S2B Fig;
S2 Table). However, by E10.5 we were not able to identify any cardiomyocyte expressing
CTCF in mutant hearts, although expression was present in endocardium (S2C and S2D Fig).
The same pattern was observed at E11.5 (S2E and S2F Fig). Persistent CTCF protein in cardio-
myocytes at E9.5, despite that Nkx2.5-Cre is active from E7.5-E8.0 [23], could be explained by
protein long half-life [24, 25]. It has been recently shown that 15% of CTCF is sufficient for
proper function [26]. Therefore, the remaining protein we observe can explain why morpho-
logical defects are not detected until E10.5.
We assessed whether cardiac defects were due to decreased cell proliferation or increased
apoptosis. Numbers of cardiomyocytes positive for TUNEL staining (S3A–S3F, S3M and S3O
Fig; S3 Table) or phosphorylated histone H3 (S3G–S3L, S3N and S3P Fig; S3 Table) were not
altered in mutant hearts at E10.5 and E11.5, indicating that apoptosis and proliferation were
unaffected. Accordingly, we did not observe a difference in the number of cardiomyocytes
between mutants and controls at these stages (S3 Table). Our results differ from others show-
ing that CTCF loss in other developmental systems cause increased apoptosis [20], suggesting
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Fig 1. Morphological defects in Ctcf mutant embryonic hearts. Whole mount control and mutant (Ctcf fl/fl;Nkx2-5-Cre) embryos at E10.5 (A, B),
E11.5 (C, D) and E12.5 (E, F). Arrows in (E) point to the pericardial edema present in mutant embryos. Higher magnification of the heart show
morphological defects in Ctcf mutant hearts becoming manifest at E12.5 (F). (G-L) Sections from control and mutant embryos stained with hematoxylin
and eosin; higher magnifications (black dashed boxes) for each are shown on the right of each section. Disorganization of the interventricular septum
and thinning of the myocardial wall is apparent in Ctcf mutant hearts at E11.5. A, atria; V, ventricle; RA, right atria; LA, left atria; RV, right ventricle; LV,
left ventricle; AVC, atrioventricular canal; IVS, interventricular septum. Scale bars, 750 μm (A), 200 μm (B, D), 1 mm (C), 2 mm (E), 800 μm (F), 100 μm
(G, H), 200 μm (I-L), and 100 μm in all higher magnifications.
https://doi.org/10.1371/journal.pgen.1006985.g001
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context-specific effects of CTCF. Our results indicate that Ctcf is required for cardiac
morphogenesis.
Transcriptional changes in the developing heart caused by Ctcf deletion
To understand the function of CTCF as a transcriptional regulator in the developing heart,
we analyzed the global effects of CTCF loss on gene transcription. We performed RNA-seq
analysis on hearts homozygous for cardiac-specific deletion of Ctcf (Ctcf fl/fl;Nkx2.5-Cre); het-
erozygotes, with deletion of only one allele (Ctcf fl/+;Nkx2.5-Cre); and control heterozygotes
for the floxed allele but not carrying the Nkx2.5-Cre driver (Ctcf fl/+). To identify the earliest
transcriptional effects of Ctcf deletion this analysis was performed at E10.5, when we first
observed a complete loss of CTCF in the mutants. Comparison between homozygous Ctcf-
deleted hearts and heterozygotes or controls yielded approximately 2,000 differentially
expressed genes in each case, of which roughly half were upregulated and half downregulated
(S4 Table). Interestingly, comparison between heterozygotes and controls returned only 24
differentially expressed genes, including Ctcf itself and11 pseudogenes (S4 Table). This sug-
gests that, at least in the developing heart [27], one functional Ctcf allele is sufficient for cor-
rect regulation of gene expression.
Gene-ontology analysis [28] of all genes differentially expressed upon Ctcf deletion showed
enrichment in terms related to developmental processes, including heart development, con-
tractile fibers, translation and mitochondria (Fig 2A; S5 and S6 Tables). When we analyzed
upregulated and downregulated genes separately, we found a clear distinction in the functional
categories enriched in each case. Numerous upregulated genes were enriched in categories
related to translation and mitochondrial function. In contrast, the downregulated genes were
over represented in categories related to heart development and the sarcomere (S5 and S6
Tables).
Detailed analysis revealed that more than 300 genes related to mitochondrial function were
up- and down regulated in Ctcf mutant hearts. Many of such genes encode subunits of mito-
chondrial respiratory complexes I, III, IV and V/ATP synthase, Sdhd in Complex II, and the
large and small mitochondrial ribosome subunits (S4A Fig; S6 Table). This could suggest that
CTCF controls expression of core transcriptional regulators of the mitochondrial gene pro-
gram. However, none of these factors, such as PGC-1α, ERRs, or NRF-1/2 [29], where dysregu-
lated in mutant hearts (S4 Table). Other upregulated genes are involved in translation and
encode most cytoplasmic ribosomal proteins, various initiation and elongation factors, and
members of the spliceosomal complex (S4B Fig; S6 Table).
Genomic features of genes dysregulated in the CTCF-deficient heart
CTCF organizes chromatin structure and contributes to the establishment of regulatory
domains in the genome [30]. We found that genes misregulated in Ctcf mutant hearts do not
cluster in specific genomic regions (S5A Fig), suggesting that CTCF does not control gene
expression in large genomic regulatory domains similarly to what has been recently shown in
embryonic stem cells [26].
We next examined CTCF chromatin binding near genes whose expression changed upon
Ctcf deletion in the heart by mapping the distance between the transcriptional start site (TSS)
and the nearest CTCF ChIP-seq peak obtained from published datasets on adult 8 week hearts
[10]. We found that the up- and downregulated genes are closer to a CTCF binding site than
genes whose expression does not change upon Ctcf deletion (S5B Fig). Arbitrarily analyzing
10 or 20 kb windows based on the above distribution, we found that TSS of down- and up-reg-
ulated genes are surrounded by CTCF binding sites more frequently than genes whose
Role of CTCF in cardiac development
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Fig 2. Transcriptional changes in Ctcf mutant hearts. (A) Iris plot showing enriched GO terms in differentially
expressed genes between control and mutant E10.5 hearts (outside circle), together with changes in expression of
individual genes (inner circle; red, upregulated in mutants; blue, downregulated). (B) Genes that are up- or
downregulated in Ctcf mutant hearts are more likely to have a CTCF binding site in their vicinity (10 or 20 kb
surrounding the transcriptional start site) than genes that are expressed in the embryonic heart but do not change.
Role of CTCF in cardiac development
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expression did not change in mutants (Fig 2B). These CTCF binding sites are conserved across
multiple tissues, and we did not observe enrichment for heart-specific CTCF peaks near genes
deregulated in the mutant. These results suggest that CTCF regulates gene expression mainly
by binding nearby genomic regions, possibly by mediating local chromatin interactions.
CTCF could define gene regulatory domains by shielding genes from the influence of
nearby enhancers or by facilitating enhancer-promoter interactions [15]. In the first scenario,
Ctcf loss would lead to upregulation of gene expression and to downregulation in the second.
To distinguish between these two possibilities, we determined the distance between dysregu-
lated genes and the nearest heart enhancer [10]. We found that downregulated, but not upre-
gulated, genes are significantly closer to a heart enhancer than expressed genes with no change
in Ctcf mutants (S5B Fig). Again, this pattern is preserved when analysis is restricted to a 10 or
20 kb window surrounding the TSS of differentially expressed genes (Fig 2B). As downregu-
lated genes are enriched in developmental regulators, these results suggest that CTCF pro-
motes enhancer-promoter interactions in genes controlling cardiac progenitor establishment
and differentiation.
The previous results suggest specific genomic features of up- or downregulated genes in
Ctcf mutant hearts. To further explore these features, we analyzed in more detail the distribu-
tion of CTCF binding peaks on the same dataset used above surrounding the TSS of dysregu-
lated genes. Up- and downregulated genes showed enrichment in CTCF binding immediately
upstream of the TSS, and the binding signal was higher than that in genes whose expression
did not change in mutants (Fig 2C), which agrees with the previous result (Fig 2B). However,
when we analyzed only the dysregulated genes belonging to development, or mitochondria
and translation categories (S6 Table) we observed a clear difference. Mitochondrial and trans-
lation genes showed increased CTCF binding near the TSS, but in developmental genes CTCF
binding spread over more distal regions (Fig 2C). We searched promoter-proximal and distal
sites for de novo and known sequence motifs to address the possibility that the presence of
CTCF sites or other motifs would underlie the differences in distribution between categories.
However, we only identified binding motifs for CTCF itself (S7 Table).
Our results suggests that Ctcf binds near the TSS to repress genes acting in mitochondria
and regulating translation, both crucial for cardiomyocyte maturation [29]. In contrast, CTCF
binding to genomic regions more distal to TSS promotes expression of genes located near
heart enhancers and controlling cardiac development.
Mitochondria do not mature properly in Ctcf mutant cardiomyocytes
Dramatic changes to the nuclear-encoded mitochondrial transcriptome, particularly of
proteins involved in oxidative phosphorylation (OXPHOS) system, in Ctcf mutant hearts
prompted us to analyze the components of this pathway in mutant and control embryonic car-
diomyocytes. In agreement with the RNA-seq (S4 Table), Western blot revealed increase in
Complex IV subunit I (Cox I, encoded in mitochondrial DNA) and Complex IV subunit IV
(Cox IV, encoded by Cox4i1) in Ctcf mutant hearts at E10.5 and E11.5, as compared to con-
trols (Fig 3A). Similarly increased was Tom20 (encoded by Tomm20) (Fig 3B), which is the
mayor receptor of the mitochondrial outer membrane translocase. The abundance of other
However, only downregulated genes are located closer to heart-specific enhancers. Frequency is expressed relative
to that of expressed but unchanged genes. *, p<0.01; **, p<0.0005; Mann-Whitney test. (C) Mean-plots of the
distribution of CTCF binding, as determined by ChIP-seq [10], relative to the TSS (0 on the x-axis) of different groups
of genes (legend on the right). Note that the peak of the distributions is located slightly upstream of the TSS, indicative
of binding to proximal promoter sequences.
https://doi.org/10.1371/journal.pgen.1006985.g002
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Fig 3. Defective mitochondrial biogenesis upon CTCF loss. Western blot of Cox I, Cox IV (A), Grp75, Tfam and Tom20 (B)
of control and mutant (Ctcf fl/fl;Nkx2-5-Cre) hearts at E10.5 and E11.5. (C) Blue native gel of control and mutant hearts at E10.5
and E11.5 showing abundance and distribution of mitochondrial respiratory complexes (CI, CIV, CVm) and supercomplexes
(CI+CIII). (D) Densitometry of blue native gel quantifying changes between E10.5 and E11.5 in complexes and supercomplexes,
in control and mutant hearts. (E) Transmission Electron Microscopy at E10.5 and E11.5 in control and mutant cardiomyocytes.
n, nucleus; sm, sarcomere. Arrowheads point to mitochondria. Scale bar, 1 μm top row, 0.5 μm bottom row.
https://doi.org/10.1371/journal.pgen.1006985.g003
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mitochondrial proteins encoded by genes whose expression did not change in Ctcf mutants
(S4 Table), such as Grp75, a key stress chaperone regulating mitochondrial protein transloca-
tion, folding and functions [31]; and Tfam, the transcriptional regulator of mitochondrial
DNA [32], was comparable between control and mutant hearts (Fig 3B).
We asked whether upregulation of OXPHOS components favors functional assembly of
respiratory complexes and supercomplexes on the mitochondrial inner membrane. Blue-
native gel electrophoresis revealed assembled complexes I, IV and V, and supercomplex I+III2
in both control and mutant hearts at E10.5 and E11.5 (Fig 3C). The mitochondrial voltage-
dependent anion channel (Vdac), whose assembly is independent of respiratory complexes
and supercomplexes, and whose encoding gene (Vdac1-3) levels did not change in mutants (S4
Table), was used as loading control. In control hearts, Complex I, both in the free form I or in
the form of I+III2, and Complex V substantially increased from E10.5 to E11.5 (Fig 3C and
3D), consistent with maturation of mitochondrial OXPHOS [4]. In contrast, levels of I+III2
and I did not increase from E10.5 to E11.5 in Ctcf mutant hearts. Complex V was similarly
increased between E10.5 and E11.5 in control and Ctcf mutant hearts (Fig 3C and 3D). This
agrees with maturation/stabilization of the electron transport chain components being regu-
lated independently of their production [33]. Our results suggest that despite increased tran-
scription of subunits of CI and CIII that may lead to more complexes and supercomplexes
assembled at the mitochondrial inner membrane, maturation of the respiratory chain is
blunted in the Ctcf mutant heart.
Transmission electron microscopy (TEM) analysis revealed immature, but overall normal
mitochondria with healthy cristae packaging in Ctcf mutant cardiomyocytes at E10.5 (Fig 3E).
Mitochondria in control E11.5 cardiomyocytes have a more electro-dense matrix containing
more cristae than E10.5, and are embedded in newly assembled sarcomere. This ultrastructure
change agrees with blue native gel electrophoresis data and is consistent with cardiomyocyte
maturation occurring between E10.5 and E11.5 [3, 4]. Mitochondria in Ctcf mutant cardio-
myocytes at E11.5 are swollen and larger than controls, and are disorganized and scattered
through the cytoplasm (Fig 3E; S6A Fig). Immunohistochemistry, targeting the mitochondrial
outer membrane component Tom20, revealed disorganized mitochondria in Ctcf mutant car-
diomyocytes at E10.5 (S6B Fig).
TEM analysis also revealed that E10.5 mutant, but not control, cardiomyocytes have long
and continuous sarcomeres, which were also visible at E11.5 (Fig 3E). Quantification on
images of cardiomyocytes from E10.5 hearts immunostained for α-actinin revealed compara-
ble numbers of sarcomeric Z-bands between control and Ctcf mutants (S6C and S6D Fig).
These results suggest that sarcomere assembly, but not sarcomeric component synthesis, is
premature in the Ctcf mutant embryonic heart.
Loss of CTCF disrupts the cardiac developmental program
The set of genes downregulated in Ctcf mutant hearts that are enriched in heart development
functional categories include key transcription factors and members of several signaling path-
ways controlling cardiac development (Fig 4A). In situ hybridization confirmed downregula-
tion of the transcription factors Nkx2-5 and Hopx in the Ctcf mutant heart at E10.5. (Fig 4B
and 4C). This analysis also showed reduced expression of Nppa to a more restricted domain in
the left ventricle, and loss of Pitx2 expression in the right ventricle (Fig 4D and 4E).
Our RNA-seq showed reciprocal up and downregulation of genes from the Tnnt1/Tnni3
and Tnni2/Tnnt3 troponin clusters (Fig 4F and 4G). Accordingly, in situ hybridization
revealed strong downregulation of Tnnt1 and Tnni2, and upregulation of Tnni3 in atria and
ventricles and of Tnnt3 in atria in the Ctcf mutant heart (Fig 4H–4K). These changes in the
Role of CTCF in cardiac development
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Fig 4. The cardiac developmental program is abrogated in Ctcf mutant hearts. (A) Deletion of Ctcf leads to
downregulation of genes encoding key cardiac developmental transcription factors and signaling-pathway components. The
heatmap shows normalized gene expression values from the RNA-seq data for controls (Ctcf fl/+), heterozygotes (Ctcf fl/+;
Nkx2.5-Cre) and homozygotes (Ctcf fl/fl;Nkx2.5-Cre) across three biological replicates each. (B-E) In situ hybridization in
sections of E10.5 control and mutant (Ctcf fl/fl;Nkx2-5-Cre) hearts for Nkx2.5 (B), Hopx (C), which are strongly downregulated;
Role of CTCF in cardiac development
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expression pattern of troponin genes, which are arranged in clusters in the genome, suggest
that CTCF coordinates their expression during development.
Irx4, which encodes a transcription factor critical for heart development [34, 35] was down-
regulated in Ctcf mutants. We analyzed this gene and its genomic context in more detail as a
means to understand the mechanisms through which CTCF regulates transcription in vivo.
Irx4 forms part of the 1.5 Mb IrxA cluster, which also contains the related Irx1 and Irx2 genes
[36]. All three IrxA genes are expressed in the developing heart, in distinct but partially over-
lapping patterns. Whereas Irx1 and Irx2 express at low levels in the interventricular septum,
Irx4 is strongly expressed throughout the ventricles [37]. Previous studies have shown that the
IrxA cluster is regulated through long-distance gene-specific interactions [38]. Furthermore,
our RNA-seq analysis revealed significant upregulation of the three genes closest to Irx4 out-
side the IrxA cluster: Ndufs6, encoding a subunit of mitochondrial Complex I; Mrpl36, encod-
ing a mitochondrial ribosomal protein; and Lpcat1, involved in phospholipid metabolism
(Fig 5A; S4 Table).
To confirm and extend these observations, we examined the expression of the three genes
in the IrxA cluster, and of their immediate neighbor Ndufs6, in control and mutant hearts by
in situ hybridization. Expression of Irx4 in mutant hearts was indistinguishable from controls
at E9.5 (Fig 5B), but expression levels were strongly reduced in mutants at E10.5 (Fig 5C) and
E11.5 (Fig 5D and 5J). The RNA-seq analysis showed that Irx1 and Irx2 expression was not sig-
nificantly different in mutants. However, in situ hybridization showed that their expression
domains expanded from the interventricular septum to the adjacent trabecular myocardium
in the right and left ventricle of Ctcf mutants (Fig 5E, 5F, 5H and 5I). In control hearts, Ndufs6
was expressed ubiquitously but with higher intensity in the ventricles, similar to Irx4, but its
expression was subtly increased in mutant hearts (Fig 5G). Together, these observations sug-
gest that loss of CTCF leads to overall dysregulation of the IrxA cluster and its neighboring
genes, perhaps through modification of its 3D structure.
CTCF regulates local chromatin structure of the IrxA cluster
To uncover the function of CTCF in regulating the IrxA chromatin structure we performed
chromosome conformation capture followed by deep sequencing (4C-seq) [39], using as view-
points the promoters of Irx4 and Ndufs6 in E11.5 control and homozygous mutant (Ctcf fl/fl;
Nkx2.5-Cre) hearts (Fig 6A and 6B; S7 Fig). In controls, the promoter of Irx4 interacted
strongly with the Irx2 promoter and with specific CTCF binding sites located upstream and
downstream in the Irx2/Irx4 and Irx4/Ndufs6 intergenic regions, respectively (asterisks in Fig
6A). The CTCF binding sites were previously identified by ChIP-seq in E14.5 and 8-week
hearts [10]). In mutants, the interaction of the Irx4 promoter with the Irx2/Irx4 intergenic
CTCF site was lost, and new interactions appeared upstream and 350 kb downstream in the
Clptm1l locus (Fig 6B). The Ndufs6 promoter established interactions with the promoters of
Irx4, Lpcat1 and Clptm1l as well as with the two intergenic CTCF sites in control hearts. In
CTCF mutants, interactions of the Ndufs6 promoter with both CTCF binding sites and the
Irx4 promoter were lost, and only contacts with the promoters of the downstream genes
Lpcat1 and Clptm1l were maintained (Fig 6B).
and Nppa (D) and Pitx2 (E), which lose expression in the left ventricle (brackets and asterisks in D) or right ventricle (arrow in
E), respectively. (F, G) Genomic region containing Tnnt1 and Tnni3 (F; mm9, chr7:4,433,080–4,493,651) or Tnni2 and Tnnt3
(G; mm9, chr7:149,623,608–149,703,181). Troponin genes are highlighted in black. (H-K) In situ hybridization in sections of
E10.5 control and mutant hearts for Tnnt1 (H), Tnni3 (I), Tnni2 (J) and Tnnt3 (K). RA, right atria; LA, left atria; RV, right
ventricle; LV, left ventricle; AVC, atrioventricular canal; IVS, interventricular septum. Scale bar, 200 μm.
https://doi.org/10.1371/journal.pgen.1006985.g004
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Fig 5. Ctcf deletion causes global changes in the expression of the IrxA cluster in the developing heart. (A) Diagram of the
extended IrxA cluster showing the location of Irx1, Irx2, Irx4 and the neighboring genes Ndufs6, Mrpl36 and Lpcat1 (not to scale).
(B-J) In situ hybridization in sections of control and mutant hearts for Irx4 at E9.5 (B), E10.5 (C) and E11.5 (D); and Irx1 (E), Irx2 (F)
and Ndufs6 (G) at E11.5. (H-I) Higher magnifications (black dashed boxes) of Irx1 (H), Irx2 (I) and Irx4 (J) expression in control and
mutant hearts at E11.5. Arrows indicate extension in the expression territories of Irx1 (H) and Irx2 (I). A,atria; V, ventricle, RA; right
atria; LA, left atria; RV, right ventricle; LV, left ventricle; AVC, atrioventricular canal; IVS, interventricular septum. Scale bars,
100 μm (B), 200 μm (C-J).
https://doi.org/10.1371/journal.pgen.1006985.g005
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Fig 6. CTCF is necessary for the correct chromatin organization of the Irx4-Ndufs6 locus. (A) ENCODE
data for CTCF binding in 8 weeks mouse heart (mm9 chr13:72700492–73802866). Asterisks indicate specific
intergenic CTCF binding sites. (B) Chromatin interaction profiles as determined by 4C-seq from the Irx4 (top)
and Ndufs6 (middle) promoters and the Irx2/Irx4 intergenic CTCF binding site (BS, bottom) in control (blue)
and mutant (KO, purple) E11.5 hearts. Heat map of z-scores > 2 of replicates (grayscale) are shown on top of
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Finally, we used a viewpoint for 4C-seq the Irx2/Irx4 intergenic CTCF site, which interacts
with the promoters of Irx4 and Ndufs6 (Fig 6B, S7 Fig). In controls, the Irx2/Irx4 intergenic
CTCF site interacts upstream and downstream of and extended region spanning Irx4, Ndufs6
and Mrpl36, and the downstream Clptm1l locus (Fig 6B). Interaction between the CTCF site
and the Irx4 promoter was greatly reduced in Ctcf mutants, reciprocating the pattern
observed when using Irx4 as viewpoint. Furthermore, novel interactions appeared that extend
to Irx2 (Fig 6B). Overall, these results suggest that CTCF plays a central role in organizing
chromatin in the Irx4 regulatory domain by mediating the interaction of several CTCF-
bound sites with various promoters in the region. Removal of CTCF from the developing
heart re-structures the local 3D organization of the extended IrxA cluster; this results in loss
of the interaction between Irx4 and Ndufs6 with flanking CTCF sites. These results also sug-
gest that CTCF limits chromatin interactions domains, as its loss causes an expansion of local
contacts.
To unambiguously demonstrate that the CTCF binding site located in the Irx2/Irx4 inter-
genic region is necessary for proper expression of Irx4, we generated a mouse line in which
we deleted such CTCF binding site using the CRISPR/Cas9 system [40] (S8 Fig). Homozygote
mice for the deletion are viable and fertile, as expected since Irx4 mutant mice are also viable
in homozygosity and only show mild hypertrophy and compromised contractility as adults
[34]. We analyzed the expression of Irx4 by in situ hybridization in E10.5 embryos from this
line. Irx4 was slightly reduced in the ventricles of the mutant line as compared with controls
(Fig 6C and 6D). Irx4 was also ectopically expressed in the oral-esophageal region (Fig 6E and
6F), in which Irx1 is normally expressed (Fig 6G). Therefore, deletion of the Irx2/Irx4 inter-
genic CTCF site leads to expansion of the expression domain of Irx4, perhaps by allowing
Irx1 regulatory elements to contact and activate Irx4. We have thus shown how CTCF is criti-
cal to maintain the correct chromatin structure across the IrxA cluster and neighboring
genes, and that specific CTCF binding sites are essential for the proper regulation of gene
expression.
Discussion
Recent years have seen substantial advances in our understanding of the relationship between
chromatin structure and gene expression. It is now clear that the spatial organization of the
genome sets constraints that determine how different functional elements (promoters, enhanc-
ers, and boundaries) interact with one another [14]. Nevertheless, we still do not fully under-
stand how this 3D structure is maintained or the role played by chromatin-bound factors in
this process. In this study we have explored how one of these factors, CTCF, regulates gene
expression and genome structure, by analyzing the effects of its loss during the development of
the mammalian heart.
Deletion of Ctcf in the developing heart rapidly leads to cardiac defects and embryonic
death. However, transcriptomic analysis shows that loss of CTCF does not lead to dysregula-
tion of gene expression across large chromosomal domains; rather, changes appear to be local,
as described in other developmental settings [20]. Upregulated and downregulated genes are
both more likely to have CTCF binding sites in their vicinity, but only downregulated genes
the interaction plots. (C-F) Irx4 in situ hybridization in E10.5 embryos from a transgenic mouse line where the
Irx2/Irx4 intergenic CTCF BS (left asterisk in A) has been deleted. (C, D) Irx4 expression in the heart; (E, F)
ectopic Irx4 expression in the oral-esophageal region of foregut. (G) Irx1 expression in the oral-esophageal
region of foregut in a wild-type E10.5 embryo. RA, right atria; LA, left atria; RV, right ventricle; LV, left ventricle;
AVC, atrioventricular canal; DA, dorsal aorta; TR, trachea; OE, oral-esophageal region. Scale bar, 200 μm (C,
D), and 100 μm (E-G).
https://doi.org/10.1371/journal.pgen.1006985.g006
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are closer to heart enhancers [10]. Downregulated genes include major regulators of the car-
diac developmental program, strongly suggesting that CTCF facilitates enhancer-promoter
interactions for these genes in a tissue-specific fashion. In contrast, upregulated genes are
highly enriched for genes involved in mitochondrial function and protein translation, which
interestingly show higher levels of CTCF binding close to their promoters. Cardiomyocyte
maturation involves an increase in the demand for energy and protein production, which is
accompanied by increased transcription of mitochondrial and ribosomal genes [8]. Cardio-
myocytes lacking CTCF prematurely activate these programs, but fail to maintain functional
mitochondria despite the increase in transcription. Therefore, we observe a premature matura-
tion of cardiomyocytes lacking CTCF, accompanied by the shutting down of developmental
and patterning processes. Nevertheless, there is a lack of coordination of this precocious differ-
entiation, leading to embryonic lethality at E12.5.
To gain insight into the relationship between CTCF, genome structure and the regulation
of gene expression, we analyzed the IrxA gene complex. This complex is a paradigm of gene
clustering [36], with genes expressed in overlapping but distinct domains in the developing
heart [37] and separated into distinct structural and regulatory domains [38]. We observed
changes in the levels and pattern of IrxA gene expression in Ctcf mutants, and interestingly
detected similar changes in unrelated genes neighboring Irx4. This strongly suggests that the
changes in the extended IrxA cluster are caused by the loss of CTCF binding in the region, and
are not a secondary effect of changes in other genes.
Analysis by 4C-seq in wild type and mutant hearts showed that when CTCF is lost, the Irx4
promoter forms fewer contacts with CTCF-flanking sites and gains interactions with regions
situated outside of its regulatory domain. Furthermore, the promoter of the mitochondrial
Ndufs6 gene also losses interactions with these CTCF sites. These changes in promoter interac-
tions in Ctcf mutants were mirrored by 4C analysis of the Irx2/Irx4 intergenic CTCF site. Con-
sequently, deletion of this CTCF site leads to reduced Irx4 cardiac expression accompanied by
gain of expression in novel territories. Therefore, in this context CTCF is acting both as an
insulator to separate adjacent regulatory domains, and as a facilitator of promoter-enhancer
interactions to ensure proper gene expression within these domains.
The structure we have defined for Irx4 is reminiscent of the recently described super-
enhancer domains (SD), where regions of a few hundred kilobases located between CTCF sites
are organized as insulated neighborhoods within large-scale topological domains [41]. The
domain we identify would contain tissue specific enhancers together with their target genes.
As is the case with SDs, loss of CTCF leads to downregulation of the gene central to this
domain (Irx4) and upregulation of flanking genes (Irx1 and Irx2 on one side; Ndufs6, Mrpl36,
and Lpcat1 on the other).
Overall, our analysis suggests that chromatin structure is relatively stable during develop-
ment and that the deletion of CTCF does not cause a marked disassembly of this organization,
in line with recent reports [42]. However, local intra-TAD domains loops [16, 43] are affected,
leading to dysregulation of genes important in the cardiac developmental program as we
observe for the IrxA genes.
More puzzling is the observation that only a limited set of genes is altered by Ctcf deletion
in the heart. CTCF binds to thousands of sites throughout the genome, most of which are
shared between different tissues and cell lines [10, 12, 44]. An essential role for CTCF in deter-
mining and maintaining chromatin structure and organization was therefore anticipated [30].
Accordingly, constitutive loss of CTCF results in very early embryonic death [17–19] and its
selective deletion in different developmental contexts leads to profound defects in the targeted
organ or tissue, usually through increased apoptosis [20–22]. However, in all of these cases
the same pattern is observed: despite wide distribution of CTCF binding, only a fraction of
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expressed genes is dysregulated. Furthermore, there is little overlap among genes regulated by
CTCF in different systems, indicating a context-specific role of this factor. In the developing
heart, we observe the concomitant upregulation and downregulation of maturation and devel-
opmental programs, suggesting that the role of CTCF here is to maintain the coordination of
expression transitions.
In this scenario, only genes subject to dynamic regulation at the time of Ctcf deletion would
show changes in expression. The description of different models of neural-specific deletion
of Ctcf is compatible with this interpretation. When deleted in precursors during neural devel-
opment, CTCF loss leads to apoptosis and subsequent death [21, 22]. However, deletion in
postnatal neurons results in long-term survival of Ctcf mutant neurons, but activity-induced
changes of gene expression are altered [45]. Together, these observations suggest that CTCF,
and possibly local chromatin structure, are not necessary for basal gene activity but essential
for dynamic transitions in expression.
Materials and methods
Ethics statement
Mice were bred in the core animal facility in the Centro Nacional de Investigaciones Cardio-
vasculares in accordance with national and European legislation. All procedures were
approved by the CNIC Committee of Animal Welfare and by the Madrid Autonomous Gov-
ernment Regional Ministry of the Environment and Territorial Organisation (reference num-
ber PROEX 196/14).
Mouse strains
The Ctcf floxed allele and Nkx2.5-Cre line have been previously described [17, 23]. Primers
used for genotyping are detailed in S8 Table. Ctcf fl/+ or Ctcf fl/fl embryos were used as controls.
Mice were bred in the core animal facility in the Centro Nacional de Investigaciones Cardio-
vasculares in accordance with national and European legislation. Some of the experiments
were performed in Toronto, and they were approved by the Toronto Centre for Phenoge-
nomics Animal Care Committee.
Histology and immunohistochemistry
Whole mount embryos were dissected in cold PBS and imaged using a Nikon SMZ1500
microscope with NIS-Elements BR 4.12.01 imaging software. For sections, embryos were col-
lected in cold PBS and fixed in 4% PFA overnight at 4˚C, dehydrated in an ethanol series,
embedded in paraffin, and sectioned at 5 μm for immunostaining amd hematoxylin and eosin,
and at 7 μm for in situ hybridization. Sections were observed under an Olympus BX51 micro-
scope and photographed with an Olympus DP71 digital camera. 5 μm paraffin sections were
incubated with CTCF 1:1500 (Bethyl labs A300-543A) and CT3 1:10 (Hybridoma Bank) or
processed for histological analysis by hematoxylin and eosin staining. For TUNEL the Termi-
nal Transferase recombinant kit (Roche 03 333 574 001) and biotin-16-dUTP (Roche 11 093
070 910) were used, together with anti-PH3 antibody 1:200 (Millipore 06–570) and CT3 1:10
(Hybridoma Bank); images were acquired with a Nikon A1R Confocal microscope.
Quantification of TUNEL and PH3 staining were performed with ImageJ software. Positive
cells for each antibody were counted in 3–5 sections per heart. Three control and three KO
hearts were used. Statistical significance was determined using one-tailed Student´s test. α-
actinin bands quantification was performed as previously described [3]. Quantification of
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CTCF staining at E9.5 was performed with ImageJ software. Positive cells for CTCF were
counted in 5 sections per heart.
For cardiomyocyte purification, individual E10.5 ventricles were dissected in cold PBS and
incubated 5 min at 37˚C with 100 μL of 48 mg/mL Collagenase type II and pancreatin 0.025gr/
mL (plus NaCl 0.0085gr/mL) diluted in ADS buffer (5x: 0.034 g/mL NaCl, 0.238 g/mL Hepes,
0.0006 g/mL NH2PO4, 0.005 g/mL glucose, 0.002 KCl, 0.001 g/mL MgSO4). After mechanical
disruption by pipetting, tubes were left 2 min in the hood, liquid phase was separated, mixed
with 100microL of cardiomyocyte media (4:1 mixture of of Dulbecco’s Modified Eagle
Medium (DMEM, 1x Gibco, 41965–039) and medium M199 (Sigma, M2154). This is supple-
mented with 15% inactivated bovine serum; 5mM HEPES, pH7.4; 2mM L-glutamine; and 1x
penicillin-streptomycin [46] and incubated at 37˚C while enzymatic and mechanical disrup-
tion was repeated. Both fractions were pooled and centrifuged at 1000 rpm at room tempera-
ture. Pellets were resuspended in 300 μL of cardiomyocyte culture media and incubated 45
min in a 24 well plate previously coated with gelatin 1% at 37˚C. Cardiomyocytes were counted
and incubated in a new 24 well plate without gelatin for 24 hrs. Cardiomyocytes were fixed
with PFA diluted in cardiomyocyte media (4% for α-actinin sarcomeric staining, 3.6% for
Tom20 staining) for 10 min at 4˚C, washed 2x with PBS and stored at 4˚C until used. Cardio-
myocytes were blocked with BSA, and incubated ON 4˚C with 1:100 Tom20 or α-actinin.
In situ hybridization
In situ hybridization using digoxigenin-labeled probes (Roche 11277073910) was performed as
described [47] and developed with anti-dioxigenin-AP (Roche 11093274910) and BM-Purple
(Roche 11442 074 001). Probes for Irx1 and Irx2 were previously described [48]. Probes for
Nkx2.5, Nppa and Pitx2 were kindly provided by Jose Luis de la Pompa (CNIC). All other
probes were generated by PCR (primers used are detailed in S8 Table), adding the sequence of
the SP6 promoter at the 5’ of forward primers and of the T7 promoter at the 5’ of reverse prim-
ers. Sections were observed under an Olympus BX51 microscope and photographed with an
Olympus DP71 digital camera.
RNA-seq analysis
RNA-seq was conducted on three pools of six E10.5 hearts each from control (Ctcf fl/+), hetero-
zygotes (Ctcf fl/+;Nkx2.5-Cre) and homozygous mutants (Ctcf fl/fl;Nkx2.5-Cre). Sequencing was
performed by the CNIC Genomics Unit using the GAIIx sequencer, and differential gene
expression analysis was performed by the CNIC Bioinformatics Unit using the transcriptome
set from Mouse Genome Reference NCBIM37 and Ensembl Gene Build version 65. GO term
enrichment was done using DAVID (http://david.abcc.ncifcrf.gov) with cut-offs of minimum
10 genes and an EASE value of 0.0001 [28, 49]. Distances between transcriptional start sites
(TSS) and between these and CTCF binding sites or predicted heart enhancers were analyzed
using R. We used ChIP-seq data for CTCF in adult 8-week hearts. Although data is also avail-
able for E14.5 embryonic hearts, its quality is much lower (one replicate with 2.8M reads for
E14.5; two replicates with over 8M reads each for 8w). Coordinates for CTCF binding sites,
and predicted heart enhancers were obtained from the Ren Lab (http://chromosome.sdsc.edu/
mouse/download.html) [10]). Heat maps were generated using R and the heatmap.2 package.
For density plots of CTCF ChIP signal, values +/- 2kb relative to the TSS were extracted with
bwtools [50] from bigWig files available at ENCODE (ENCSR000CBI), and z-scores were cal-
culated transforming each value by substracting the mean over each chromosome and dividing
by the standard deviation. After a smoothing step results were plotted using in-house scripts
in R. The observed distances between TSS of gene-sets were compared with the expected
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proportion calculated from 5,000 groups randomly sampled without replacement taken from
all expressed genes. To identify heart-specific CTCF sites, we first merged all sites identified
across multiple tissues from the ENCODE data (121,147 sites) and subtracted these from the
set of sites bound in heart. This analysis rendered only 1,432 heart-specific peaks that were not
enriched near different sets of deregulated genes in the Ctcf mutant.
For known motif enrichment and de novo motif search using Homer [51], we defined the
promoter-proximal region as the 200 bp immediately upstream from the TSS of differential-
expressed genes belonging to each of the “development”, “translation” and “mitochondria”
categories, and the distal region as the next 1.8 kb upstream and the 2 kb downstream of the
TSSs. We then identified all CTCF peaks present in these regions for each category, and used
the 200 bp sequences surrounding the summit of CTCF peaks as input. As a background, we
used 2 kb upstream of the TSSs of genes expressed but unchanged in our RNAseq data that
had no CTCF peaks in that region (8,445 genes). As cut-offs we used p-value < 1e-10 for de
novo motif search, and a Benjamini adjusted p-value < 0,001 for known motif enrichment.
All sequencing data has been deposited at GEO under accession number GSE77644.
Western blot analysis
Hearts lysates of E10.5 and E11.5 prepared in RIPA buffer were separated by 12.5% SDS polya-
crylaimde gel electrophoresis (SDS PAGE) and electroblotted onto PVDF transfer membrane
(BioRad). For protein detection, the following antibodies were used: CoI (Complex IV subunit
I; Invitrogen), Tom20 (Santa Cruz Biotech), αActin (Sigma Aldrich), CoxIV (Complex IV
subunit IV), Grp75 and mtFA (Abcam). Quantification of signals arising from near-infrared
(NIR) fluoropnores conjugated to secondary antibodies was performed by two-channel infra-
red (IR) scanner (Odyssey v.3.0). Representative gels are shown in figures (n = 3–4).
Blue native gel electrophoresis
Mitochondrial isolation from E10.5 and E11.5 hearts were carried out in duplicate, as
described [52] with some modifications. Pools of 4 embryonic hearts were homogenized in a
glass homogenizer in buffer A (Sucrose 0,32M; Tris 10mM, EDTA 1mM; pH7,4). After centri-
fugation at 1000g, the nuclei were discarded and mitochondria were collected from the super-
natant by a new centrifugation at 12000g. Mitochondrial proteins were solubilized with
digitonin (4g/g) (Sigma D5628) and run on a 3%–13% gradient Blue Native gel as described
[53]. After electrophoresis, the complexes were electroblotted onto PVDF membrane (Merck-
millipore, IPFL00010) and sequentially probed with specific antibodies against Complex I
(anti-Ndufa9, ab14713), Complex III (anti-core1, ab110252), Complex IV (anti-CoI, Invitro-
gen ref.459600), ATPsyntase (anti-ATPB, ab14730) and VDAC1 (anti-VDA1C, ab14734).
Transmission electron microscopy (TEM)
Embryonic hearts from E10.5 and E11.5 were isolated from the specified genotype (n = 3).
Samples were fixed in 2.5% glutaraldehyde (Sigma-Aldrich), 4% formaldehyde (Electron
Microscopy Sciences) in 0.1M HEPES buffer for 3–4 h at 4˚C, and processed as previously
described [54]. Briefly, after buffer washes samples were post-fixed for 1h at room temperature
in a 1:1 solution of 2% osmium tetroxide (Electron Microscopy Sciences) and 3% aqueous
potassium ferrocyanide (Sigma-Aldrich). Samples were rinsed in distilled water. Tissues were
dehydrated through a graded acetone series and embedded in Spurr’s Low Viscosity embed-
ding mixture (Electron Microscopy Sciences). Ultrathin sections (60 nm) were then mounted
on copper grids and stained with lead citrate. Samples were examined on a JEOL 10–10 elec-
tron microscope and analyzed by ImageJ v.1.6.0 Software.
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4C-sequencing
4C was performed as previously described [55, 56]. Briefly, hearts were dissected from control
and mutant (Ctcf fl/fl;Nkx2.5-Cre) E11.5 embryos (in order to be able to obtain more starting
material). Each heart was minced and passed throw a 70 micrometers cell strainer, crosslinked
with 2% PFA, frozen with liquid nitrogen, and stored at -80˚ for later processing once geno-
types were established. Pools of 45–65 hearts from controls or mutants were lysed and digested
first with DpnII (New England Biolabs, cat.no. R0543M) followed by Csp6I (Fermentas, cat.no.
ER0211). For all experiments, 100 to 200 ng of the resulting 4C template was used for the sub-
sequent PCR reaction (primers used are detailed in S8 Table). Sequencing was performed by
the CNIC Genomics Unit. All sequencing data has been deposited at GEO under accession
number GSE77644.
4C-seq data analysis
For sample comparison between controls and mutants, 4C-seq data was normalized by total
weight in a window of 15 Mb surrounding the IrxA cluster. The mean and standard deviation
for each fragment were calculated for each group of replicates, and the difference was deter-
mined between the means in control and mutants for each viewpoint. Data were compared
using the R package edgeR [57], which applies statistical tests based on negative binomial
distributions.
For contact estimation, aligned reads were assigned to their corresponding virtual first cut-
ter digested genome fragment. Each fragment end was considered as a captured site (ligated to
the viewpoint) if one or more sequences mapped to it starting at the end of the fragment and
in the right orientation, facing the center of the fragment. The number of captured sites was
summarized per 30 fragment window (max of 60 captured sites per window). The frequency
of captured sites per window was used to fit a distance decreasing monotone function and z-
scores were calculated from its residuals using a modified version of FourCSeq [58]. Significant
contacts were considered in cases where the z-score was>2 in both replicates and deviated sig-
nificantly (adjusted p value<0.05) from its normal cumulative distribution in at least one of
the replicates.
CRISPR/Cas9 genomic deletions
Two guide RNAs (g5.3-g3; S8 Table), together with the Cas9 protein with NLS (PNA Bio),
were injected into the pronucleus of E0.5 B6/CBA F1 embryos, which were then transferred to
CD1 pseudo-pregnant females. Guide RNAs were injected at 25ng-μL, and the Cas9 protein at
30 ng/μL. Embryos from the established line were collected at E10.5 and processed for in situ
hybridization and genotyping (primers listed in S8 Table).
Supporting information
S1 Fig. Nkx2.5-Cre/+ and Ctcf fl/+;Nkx2.5-Cre/+ heterozygotes show no cardiac defects.
Hematoxylin and eosin staining at E9.5 (A-F), E10.5 (G-L), and E11.5 (M-R) of control (A, B,
G, H, M, N), Ctcf fl/+;Nkx2.5-Cre (C, D, I, J, O, P) and Nkx2.5-Cre heterozygous embryos (E, F,
K, L, Q, R). Higher magnifications (black dashed boxes) for each section are shown below. A,
atria; V, ventricle; AVC, atrioventricular canal; RA, right atria; RV, right ventricle; LA, left
atria; RA, right ventricle; IVS, interventricular septum. Scale bars, 100 μm (A, G, M) and
200 μm (B, H, N).
(TIF)
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S2 Fig. CTCF is lost at E10.5 in Ctcf fl/fl;Nkx2.5-Cre mutant hearts. Immunofluorescence for
CTCF (red) and cardiac troponin T (CT3, green) in sections of control and mutant hearts
(Ctcf fl/fl;Nkx2.5-Cre) at E9.5 (A, B), E10.5 (C, D) and E11.5 (E, F). Higher magnifications
(white dashed boxes) of each section are shown below. Arrowheads point to CT3 positive car-
diomyocytes show that loose CTCF signal in the mutants in comparison with the control.
Arrows point to endocardial cells that express CTCF at comparable levels in mutant and con-
trol hearts. A, atria; V, ventricle; RA, right atria; LA, left atria; RV, right ventricle; LV, left ven-
tricle; AVC, atrioventricular canal; IVS, interventricular septum. Scale bars, 100 μm (E9.5,
higher magnification of E10.5) or 200 μm (E10.5, E11.5).
(TIF)
S3 Fig. CTCF loss does not affect apoptosis or proliferation in the developing heart. Cell
death (A-F) and proliferation (G-L) in control and mutant (Ctcf fl/fl;Nkx2-5-Cre) hearts at
E10.5. Cardiomyocytes are labelled with CT3 antibody (white; A, B, G, H), TUNEl (green (C,
D) or phosphohistone 3 antibody (red, I, J). Arrowheads in merged images (E, F, K, L) point to
positive nuclei. Quantifications of TUNEL and PH3 in cardiomyocytes at E10.5 (M, N) and
E11.5 (O, P) showed no significant difference. RA, right atria; LA, left atria; RV, right ventricle;
LV, left ventricle; AVC, atrioventricular canal. Scale bar, 200 μm.
(TIF)
S4 Fig. Functional annotation of genes dysregulated by Ctcf deletion in the developing
heart. Detailed GO term enrichment in gene dysregulated in cardiac Ctcf mutants related to
mitochondria (A) and translation (B).
(TIF)
S5 Fig. Chromosomal distribution and genomic features of genes dysregulated by Ctcf
deletion in the developing heart. (A) Distances between differentially regulated (brown),
upregulated (yellow) or downregulated (blue) genes in Ctcf mutants. Dashed lines show the
distribution of random permutation tests. (B) Distribution of distances from the nearest CTCF
binding site (left panel) or heart enhancer (right panel) to the transcriptional start sites (TSS)
of downregulated, upregulated, and expressed but unchanged genes in Ctcf mutant hearts.
 p< 10e-10 versus expressed but unchanged genes; Mann-Withney test.
(TIF)
S6 Fig. Cellular phenotypes of Ctcf mutant cardiomyocytes. (A) Transmission Electron
Microscopy showing balloning of mitochondria from mutant E11.5 cardiomyocytes that also
have poorly organized crests. Scale bar, 1 μm. (B, C) Immunofluorecsence for Tom20 (B) and
for sarcomeric α-actinin (C) in E10.5 control and mutant cardiomyocytes. Scale bars 20 μm
(B-C). (D) Quantification of α-actinin bands per cell at E10.5 in control and mutant cardio-
myocytes ns, not significant.
(TIF)
S7 Fig. 4C-seq analysis of the Irx4-Ndufs6 locus in control and Ctcf fl/fl;Nkx2.5-Cre mutant
hearts. (A) ENCODE data for CTCF binding in 8 weeks mouse heart (mm9 chr13:72700492–
73802866). (B) 4C-seq profiles using viewpoints from the Irx4 (red) and Ndufs6 (green) pro-
moters, and the Irx2/Irx4 intergenic CTCF BS (blue) in control and mutant (KO) E11.5 hearts.
Dark shading depicts the mean interaction profile; lighter shading represents the standard
deviation of replicates. Arrowheads indicate the location of the viewpoint.
(TIF)
S8 Fig. CRISPR/Cas9 mediated deletion of the Irx2-Irx4 intergenic CTCF bidning site.
(A) Top, ENCODE data for CTCF binding in 8 weeks mouse heart (mm9 chr13:72700492–
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73802866). The Irx2/Irx4 intergenic CTCF BS is highlighted in green. Bottom, schematic
representation of the location of the guide-RNAs used for genome editing of the CTCF BS.
(B) Sequence of the wild type (wt) and deleted (del) alleles of the CTCF BS deleted. In red are
the gRNAs sequences are indicate in red, and PAM sequences in bold lettering. (C) PCR geno-
typing of the different genotypes from the CTCF BS deleted mouse line.
(TIF)
S1 Table. Genotypes of live embryos obtained from♂Ctcf fl/+;Nkx2.5-Cretg/+ X♀Ctcf fl/fl
crosses.
(PDF)
S2 Table. Quantification of double positive CT3-CTCF nuclei in E9.5 mutant hearts.
(PDF)
S3 Table. Quantification of proliferation and apoptosis in E10.5-E11.5 control and mutant
hearts.
(PDF)
S4 Table. RNA-seq analysis of Ctcf fl/+, Ctcf fl/+;Nkx2.5-Cre and Ctcf fl/fl;Nkx2.5-Cre E10.5
hearts.
(XLSX)
S5 Table. Gene ontology analysis of differentially expressed genes between E10.5 control
and mutant hearts.
(XLSX)
S6 Table. Genes and functional annotations used to build Fig 2A and S3A and S3B Fig.
(XLSX)
S7 Table. Motif discovery in proximal and distal CTCF peaks of dysregulated genes in
Ctcf fl/fl;Nkx2.5-Cretg/+ E10.5 hearts.
(PDF)
S8 Table. Primers and oligonucleotides used in this study.
(PDF)
Acknowledgments
We thank Sergio Menchero for help in embryo work, Laura Caporiccio for animal husbandry
and technical assistance, the CNIC Genomics and Bioinformatics Units for help and assis-
tance, Jose´ Luis de la Pompa for reagents, the ICTS-CNME (UCM) for technical support, and
Simon Bartlett for English editing.
Author Contributions
Conceptualization: Melisa Gomez-Velazquez, Jose Luis Gomez-Skarmeta, Miguel
Manzanares.
Data curation: Juan J. Tena, Carlos Torroja, Fatima Sanchez-Cabo.
Formal analysis: Melisa Gomez-Velazquez, Claudio Badia-Careaga, Ana Victoria Lechuga-
Vieco, Rocio Nieto-Arellano, Juan J. Tena, Alba Alvarez, Carlos Torroja, Eva F. Caceres,
Fatima Sanchez-Cabo, Jose Antonio Enriquez.
Funding acquisition: Paul Delgado-Olguin, Jose Luis Gomez-Skarmeta, Miguel Manzanares.
Role of CTCF in cardiac development
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1006985 August 28, 2017 21 / 25
Investigation: Melisa Gomez-Velazquez, Claudio Badia-Careaga, Ana Victoria Lechuga-
Vieco, Rocio Nieto-Arellano, Isabel Rollan, Alba Alvarez, Anna R. Roy, Paul Delgado-
Olguin, Jose Antonio Enriquez.
Methodology: Melisa Gomez-Velazquez.
Project administration: Jose Luis Gomez-Skarmeta, Miguel Manzanares.
Resources: Niels Galjart.
Software: Juan J. Tena, Alba Alvarez, Carlos Torroja, Fatima Sanchez-Cabo.
Supervision: Paul Delgado-Olguin, Fatima Sanchez-Cabo, Jose Antonio Enriquez, Jose Luis
Gomez-Skarmeta, Miguel Manzanares.
Validation: Melisa Gomez-Velazquez, Claudio Badia-Careaga, Miguel Manzanares.
Visualization: Melisa Gomez-Velazquez, Claudio Badia-Careaga, Ana Victoria Lechuga-
Vieco, Rocio Nieto-Arellano, Isabel Rollan, Alba Alvarez, Eva F. Caceres, Paul Delgado-
Olguin, Fatima Sanchez-Cabo, Jose Antonio Enriquez, Jose Luis Gomez-Skarmeta, Miguel
Manzanares.
Writing – original draft: Melisa Gomez-Velazquez, Niels Galjart, Paul Delgado-Olguin,
Fatima Sanchez-Cabo, Jose Antonio Enriquez, Jose Luis Gomez-Skarmeta, Miguel
Manzanares.
Writing – review & editing: Melisa Gomez-Velazquez, Paul Delgado-Olguin, Jose Antonio
Enriquez, Jose Luis Gomez-Skarmeta, Miguel Manzanares.
References
1. Olson EN. Gene regulatory networks in the evolution and development of the heart. Science. 2006; 313
(5795):1922–7. https://doi.org/10.1126/science.1132292 PMID: 17008524
2. Hirschy A, Schatzmann F, Ehler E, Perriard JC. Establishment of cardiac cytoarchitecture in the devel-
oping mouse heart. Dev Biol. 2006; 289(2):430–41. https://doi.org/10.1016/j.ydbio.2005.10.046 PMID:
16337936
3. Hom JR, Quintanilla RA, Hoffman DL, de Mesy Bentley KL, Molkentin JD, Sheu SS, et al. The perme-
ability transition pore controls cardiac mitochondrial maturation and myocyte differentiation. Dev Cell.
2011; 21(3):469–78. https://doi.org/10.1016/j.devcel.2011.08.008 PMID: 21920313
4. Beutner G, Eliseev RA, Porter GA Jr. Initiation of electron transport chain activity in the embryonic heart
coincides with the activation of mitochondrial complex 1 and the formation of supercomplexes. PLoS
One. 2014; 9(11):e113330. https://doi.org/10.1371/journal.pone.0113330 PMID: 25427064
5. Soonpaa MH, Kim KK, Pajak L, Franklin M, Field LJ. Cardiomyocyte DNA synthesis and binucleation
during murine development. Am J Physiol. 1996; 271(5 Pt 2):H2183–9. PMID: 8945939
6. Bruneau BG. Transcriptional regulation of vertebrate cardiac morphogenesis. Circ Res. 2002; 90
(5):509–19. PMID: 11909814
7. Paige SL, Thomas S, Stoick-Cooper CL, Wang H, Maves L, Sandstrom R, et al. A temporal chromatin
signature in human embryonic stem cells identifies regulators of cardiac development. Cell. 2012; 151
(1):221–32. https://doi.org/10.1016/j.cell.2012.08.027 PMID: 22981225
8. Wamstad JA, Alexander JM, Truty RM, Shrikumar A, Li F, Eilertson KE, et al. Dynamic and coordinated
epigenetic regulation of developmental transitions in the cardiac lineage. Cell. 2012; 151(1):206–20.
https://doi.org/10.1016/j.cell.2012.07.035 PMID: 22981692
9. Consortium EP. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012; 489
(7414):57–74. https://doi.org/10.1038/nature11247 PMID: 22955616
10. Shen Y, Yue F, McCleary DF, Ye Z, Edsall L, Kuan S, et al. A map of the cis-regulatory sequences in
the mouse genome. Nature. 2012; 488(7409):116–20. https://doi.org/10.1038/nature11243 PMID:
22763441
11. de Wit E, de Laat W. A decade of 3C technologies: insights into nuclear organization. Genes Dev. 2012;
26(1):11–24. https://doi.org/10.1101/gad.179804.111 PMID: 22215806
Role of CTCF in cardiac development
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1006985 August 28, 2017 22 / 25
12. Dixon JR, Selvaraj S, Yue F, Kim A, Li Y, Shen Y, et al. Topological domains in mammalian genomes
identified by analysis of chromatin interactions. Nature. 2012; 485(7398):376–80. https://doi.org/10.
1038/nature11082 PMID: 22495300
13. Jin F, Li Y, Dixon JR, Selvaraj S, Ye Z, Lee AY, et al. A high-resolution map of the three-dimensional
chromatin interactome in human cells. Nature. 2013; 503(7475):290–4. https://doi.org/10.1038/
nature12644 PMID: 24141950
14. Bonora G, Plath K, Denholtz M. A mechanistic link between gene regulation and genome architecture in
mammalian development. Curr Opin Genet Dev. 2014; 27:92–101. https://doi.org/10.1016/j.gde.2014.
05.002 PMID: 24998386
15. Ong CT, Corces VG. CTCF: an architectural protein bridging genome topology and function. Nat Rev
Genet. 2014; 15(4):234–46. https://doi.org/10.1038/nrg3663 PMID: 24614316
16. Rao SS, Huntley MH, Durand NC, Stamenova EK, Bochkov ID, Robinson JT, et al. A 3D map of the
human genome at kilobase resolution reveals principles of chromatin looping. Cell. 2014; 159(7):1665–
80. https://doi.org/10.1016/j.cell.2014.11.021 PMID: 25497547
17. Heath H, Ribeiro de Almeida C, Sleutels F, Dingjan G, van de Nobelen S, Jonkers I, et al. CTCF regu-
lates cell cycle progression of alphabeta T cells in the thymus. EMBO J. 2008; 27(21):2839–50. https://
doi.org/10.1038/emboj.2008.214 PMID: 18923423
18. Wan LB, Pan H, Hannenhalli S, Cheng Y, Ma J, Fedoriw A, et al. Maternal depletion of CTCF reveals
multiple functions during oocyte and preimplantation embryo development. Development. 2008; 135
(16):2729–38. https://doi.org/10.1242/dev.024539 PMID: 18614575
19. Moore JM, Rabaia NA, Smith LE, Fagerlie S, Gurley K, Loukinov D, et al. Loss of maternal CTCF is
associated with peri-implantation lethality of Ctcf null embryos. PLoS One. 2012; 7(4):e34915. https://
doi.org/10.1371/journal.pone.0034915 PMID: 22532833
20. Soshnikova N, Montavon T, Leleu M, Galjart N, Duboule D. Functional analysis of CTCF during mam-
malian limb development. Dev Cell. 2010; 19(6):819–30. https://doi.org/10.1016/j.devcel.2010.11.009
PMID: 21145498
21. Watson LA, Wang X, Elbert A, Kernohan KD, Galjart N, Berube NG. Dual effect of CTCF loss on neuro-
progenitor differentiation and survival. J Neurosci. 2014; 34(8):2860–70. https://doi.org/10.1523/
JNEUROSCI.3769-13.2014 PMID: 24553927
22. Hirayama T, Tarusawa E, Yoshimura Y, Galjart N, Yagi T. CTCF is required for neural development and
stochastic expression of clustered Pcdh genes in neurons. Cell Rep. 2012; 2(2):345–57. https://doi.org/
10.1016/j.celrep.2012.06.014 PMID: 22854024
23. Stanley EG, Biben C, Elefanty A, Barnett L, Koentgen F, Robb L, et al. Efficient Cre-mediated deletion
in cardiac progenitor cells conferred by a 3’UTR-ires-Cre allele of the homeobox gene Nkx2-5. Int J Dev
Biol. 2002; 46(4):431–9. PMID: 12141429
24. Quitschke WW, Taheny MJ, Fochtmann LJ, Vostrov AA. Differential effect of zinc finger deletions on
the binding of CTCF to the promoter of the amyloid precursor protein gene. Nucleic Acids Res. 2000; 28
(17):3370–8. PMID: 10954607
25. Nikolic T, Movita D, Lambers ME, Ribeiro de Almeida C, Biesta P, Kreefft K, et al. The DNA-binding fac-
tor Ctcf critically controls gene expression in macrophages. Cell Mol Immunol. 2014; 11(1):58–70.
https://doi.org/10.1038/cmi.2013.41 PMID: 24013844
26. Nora EP, Goloborodko A, Valton A-L, Gibcus JH, Uebersohn A, Abdennur N, et al. Targeted Degrada-
tion of CTCF Decouples Local Insulation of Chromosome Domains from Genomic Compartmentaliza-
tion. Cell. 2017; 169(5):930–44.e22. https://doi.org/10.1016/j.cell.2017.05.004 PMID: 28525758
27. Kemp CJ, Moore JM, Moser R, Bernard B, Teater M, Smith LE, et al. CTCF haploinsufficiency destabi-
lizes DNA methylation and predisposes to cancer. Cell Rep. 2014; 7(4):1020–9. https://doi.org/10.1016/
j.celrep.2014.04.004 PMID: 24794443
28. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using
DAVID bioinformatics resources. Nat Protoc. 2009; 4(1):44–57. https://doi.org/10.1038/nprot.2008.211
PMID: 19131956
29. Dorn GW 2nd, Vega RB, Kelly DP. Mitochondrial biogenesis and dynamics in the developing and dis-
eased heart. Genes Dev. 2015; 29(19):1981–91. https://doi.org/10.1101/gad.269894.115 PMID:
26443844
30. Phillips JE, Corces VG. CTCF: master weaver of the genome. Cell. 2009; 137(7):1194–211. https://doi.
org/10.1016/j.cell.2009.06.001 PMID: 19563753
31. Yaguchi T, Aida S, Kaul SC, Wadhwa R. Involvement of mortalin in cellular senescence from the per-
spective of its mitochondrial import, chaperone, and oxidative stress management functions. Ann N Y
Acad Sci. 2007; 1100:306–11. https://doi.org/10.1196/annals.1395.032 PMID: 17460192
Role of CTCF in cardiac development
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1006985 August 28, 2017 23 / 25
32. Falkenberg M, Larsson NG, Gustafsson CM. DNA replication and transcription in mammalian mitochon-
dria. Annu Rev Biochem. 2007; 76:679–99. https://doi.org/10.1146/annurev.biochem.76.060305.
152028 PMID: 17408359
33. Guaras A, Perales-Clemente E, Calvo E, Acin-Perez R, Loureiro-Lopez M, Pujol C, et al. The CoQH2/
CoQ Ratio Serves as a Sensor of Respiratory Chain Efficiency. Cell Rep. 2016; 15(1):197–209. https://
doi.org/10.1016/j.celrep.2016.03.009 PMID: 27052170
34. Bruneau BG, Bao ZZ, Fatkin D, Xavier-Neto J, Georgakopoulos D, Maguire CT, et al. Cardiomyopathy
in Irx4-deficient mice is preceded by abnormal ventricular gene expression. Mol Cell Biol. 2001; 21
(5):1730–6. https://doi.org/10.1128/MCB.21.5.1730-1736.2001 PMID: 11238910
35. Bao ZZ, Bruneau BG, Seidman JG, Seidman CE, Cepko CL. Regulation of chamber-specific gene
expression in the developing heart by Irx4. Science. 1999; 283(5405):1161–4. PMID: 10024241
36. Gomez-Skarmeta JL, Modolell J. Iroquois genes: genomic organization and function in vertebrate neu-
ral development. Curr Opin Genet Dev. 2002; 12(4):403–8. PMID: 12100884
37. Kim KH, Rosen A, Bruneau BG, Hui CC, Backx PH. Iroquois homeodomain transcription factors in
heart development and function. Circ Res. 2012; 110(11):1513–24. https://doi.org/10.1161/
CIRCRESAHA.112.265041 PMID: 22628575
38. Tena JJ, Alonso ME, de la Calle-Mustienes E, Splinter E, de Laat W, Manzanares M, et al. An evolution-
arily conserved three-dimensional structure in the vertebrate Irx clusters facilitates enhancer sharing
and coregulation. Nat Commun. 2011; 2:310. https://doi.org/10.1038/ncomms1301 PMID: 21556064
39. Simonis M, Kooren J, de Laat W. An evaluation of 3C-based methods to capture DNA interactions. Nat
Methods. 2007; 4(11):895–901. https://doi.org/10.1038/nmeth1114 PMID: 17971780
40. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al. Multiplex genome engineering using CRISPR/
Cas systems. Science. 2013; 339(6121):819–23. https://doi.org/10.1126/science.1231143 PMID:
23287718
41. Dowen JM, Fan ZP, Hnisz D, Ren G, Abraham BJ, Zhang LN, et al. Control of cell identity genes occurs
in insulated neighborhoods in mammalian chromosomes. Cell. 2014; 159(2):374–87. https://doi.org/10.
1016/j.cell.2014.09.030 PMID: 25303531
42. Zuin J, Dixon JR, van der Reijden MI, Ye Z, Kolovos P, Brouwer RW, et al. Cohesin and CTCF differen-
tially affect chromatin architecture and gene expression in human cells. Proc Natl Acad Sci U S A. 2014;
111(3):996–1001. https://doi.org/10.1073/pnas.1317788111 PMID: 24335803
43. Smallwood A, Ren B. Genome organization and long-range regulation of gene expression by enhanc-
ers. Curr Opin Cell Biol. 2013; 25(3):387–94. https://doi.org/10.1016/j.ceb.2013.02.005 PMID:
23465541
44. Martin D, Pantoja C, Fernandez Minan A, Valdes-Quezada C, Molto E, Matesanz F, et al. Genome-
wide CTCF distribution in vertebrates defines equivalent sites that aid the identification of disease-asso-
ciated genes. Nat Struct Mol Biol. 2011; 18(6):708–14. https://doi.org/10.1038/nsmb.2059 PMID:
21602820
45. Sams DS, Nardone S, Getselter D, Raz D, Tal M, Rayi PR, et al. Neuronal CTCF Is Necessary for
Basal and Experience-Dependent Gene Regulation, Memory Formation, and Genomic Structure of
BDNF and Arc. Cell Rep. 2016; 17(9):2418–30. https://doi.org/10.1016/j.celrep.2016.11.004 PMID:
27880914
46. Brand NJ, Lara-Pezzi E, Rosenthal N, Barton PJ. Analysis of cardiac myocyte biology in transgenic
mice: a protocol for preparation of neonatal mouse cardiac myocyte cultures. Methods Mol Biol. 2010;
633:113–24. https://doi.org/10.1007/978-1-59745-019-5_9 PMID: 20204624
47. Luna-Zurita L, Prados B, Grego-Bessa J, Luxan G, del Monte G, Benguria A, et al. Integration of a
Notch-dependent mesenchymal gene program and Bmp2-driven cell invasiveness regulates murine
cardiac valve formation. J Clin Invest. 2010; 120(10):3493–507. https://doi.org/10.1172/JCI42666
PMID: 20890042
48. Bosse A, Zulch A, Becker MB, Torres M, Gomez-Skarmeta JL, Modolell J, et al. Identification of the ver-
tebrate Iroquois homeobox gene family with overlapping expression during early development of the
nervous system. Mech Dev. 1997; 69(1–2):169–81. PMID: 9486539
49. Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the compre-
hensive functional analysis of large gene lists. Nucleic Acids Res. 2009; 37(1):1–13. https://doi.org/10.
1093/nar/gkn923 PMID: 19033363
50. Pohl A, Beato M. bwtool: a tool for bigWig files. Bioinformatics. 2014; 30(11):1618–9. https://doi.org/10.
1093/bioinformatics/btu056 PMID: 24489365
51. Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, et al. Simple combinations of lineage-deter-
mining transcription factors prime cis-regulatory elements required for macrophage and B cell identities.
Mol Cell. 2010; 38(4):576–89. https://doi.org/10.1016/j.molcel.2010.05.004 PMID: 20513432
Role of CTCF in cardiac development
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1006985 August 28, 2017 24 / 25
52. Fernandez-Vizarra E, Lopez-Perez MJ, Enriquez JA. Isolation of biogenetically competent mitochondria
from mammalian tissues and cultured cells. Methods. 2002; 26(4):292–7. https://doi.org/10.1016/
S1046-2023(02)00034-8 PMID: 12054919
53. Schagger H. Native electrophoresis for isolation of mitochondrial oxidative phosphorylation protein
complexes. Methods Enzymol. 1995; 260:190–202. PMID: 8592444
54. Latorre-Pellicer A, Moreno-Loshuertos R, Lechuga-Vieco AV, Sanchez-Cabo F, Torroja C, Acin-Perez
R, et al. Mitochondrial and nuclear DNA matching shapes metabolism and healthy ageing. Nature.
2016; 535(7613):561–5. https://doi.org/10.1038/nature18618 PMID: 27383793
55. van de Werken HJ, Landan G, Holwerda SJ, Hoichman M, Klous P, Chachik R, et al. Robust 4C-seq
data analysis to screen for regulatory DNA interactions. Nat Methods. 2012; 9(10):969–72. https://doi.
org/10.1038/nmeth.2173 PMID: 22961246
56. van Weerd JH, Badi I, van den Boogaard M, Stefanovic S, van de Werken HJ, Gomez-Velazquez M,
et al. A large permissive regulatory domain exclusively controls Tbx3 expression in the cardiac conduc-
tion system. Circ Res. 2014; 115(4):432–41. https://doi.org/10.1161/CIRCRESAHA.115.303591 PMID:
24963028
57. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression
analysis of digital gene expression data. Bioinformatics. 2010; 26(1):139–40. https://doi.org/10.1093/
bioinformatics/btp616 PMID: 19910308
58. Klein FA, Pakozdi T, Anders S, Ghavi-Helm Y, Furlong EE, Huber W. FourCSeq: analysis of 4C
sequencing data. Bioinformatics. 2015; 31(19):3085–91. https://doi.org/10.1093/bioinformatics/btv335
PMID: 26034064
Role of CTCF in cardiac development
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1006985 August 28, 2017 25 / 25
